|
Oct 13
|
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Expressing PD-L1 (CPS ≥1)
|
|
Oct 12
|
(MRK) Rises As Market Takes a Dip: Key Facts
|
|
Oct 12
|
15 Worst Performing Dow Stocks YTD
|
|
Oct 12
|
25 US Cities with Cleanest Air and Water
|
|
Sep 28
|
The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy
|
|
Sep 28
|
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
|
|
Sep 27
|
Top Stock Reports for Alphabet, Exxon Mobil & Merck
|
|
Sep 27
|
Merck & Co., Inc.'s (NYSE:MRK) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
|
|
Sep 25
|
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
|
|
Sep 25
|
10 Best Ways to Prevent Type 2 Diabetes
|
|
Sep 12
|
12 Best Pharma ETFs
|
|
Sep 11
|
Moderna enters cancer collaboration with Immatics worth $1.8B
|
|
Sep 11
|
Reasons for the Rise of Merck & Co. (MRK) in Q2
|
|
Sep 11
|
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
|
|
Sep 9
|
Why It Might Not Make Sense To Buy Merck & Co., Inc. (NYSE:MRK) For Its Upcoming Dividend
|
|
Sep 7
|
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%
|
|
Sep 7
|
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
|
|
Sep 6
|
15 Stocks to Buy with Steady Dividends
|
|
Sep 5
|
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
|
|
Sep 3
|
Possible Bearish Signals With Merck Insiders Disposing Stock
|